TD Cowen Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $110
Lantheus Stock Buy Rating Supported by Increased Pylarify Revenue Projections and Updated EPS Estimates
Lantheus Holdings Analyst Ratings
B. Riley Cuts Price Target on Lantheus Holdings to $122 From $127, Keeps Buy Rating
William Blair Maintains Lantheus(LNTH.US) With Hold Rating
William Blair Remains a Hold on Lantheus (LNTH)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Certara (CERT), Lantheus (LNTH) and Mirum Pharmaceuticals (MIRM)
JonesTrading Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $134
Lantheus Holdings Analyst Ratings
Truist Financial Maintains Lantheus(LNTH.US) With Buy Rating, Announces Target Price $127
Mizuho Securities Maintains Lantheus(LNTH.US) With Buy Rating, Cuts Target Price to $140
Analysts Offer Insights on Healthcare Companies: Lantheus (LNTH) and Argenx Se (ARGX)
A Quick Look at Today's Ratings for Lantheus(LNTH.US), With a Forecast Between $110 to $127
Lantheus: Strong Revenue Growth and Strategic Partnerships Justify Buy Rating
William Blair Keeps Their Hold Rating on Lantheus (LNTH)
Analysts Conflicted on These Healthcare Names: Halozyme (HALO), Stoke Therapeutics (STOK) and Lantheus (LNTH)
Jefferies Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $135
TD Cowen Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $110
Truist Financial Maintains Lantheus(LNTH.US) With Buy Rating
JonesTrading Maintains Lantheus(LNTH.US) With Buy Rating, Raises Target Price to $134